Metabolic variables of obese dogs with insulin resistance supplemented with yeast beta-glucan

Background Obesity is one of the most common nutritional disorders in dogs and cats and is related to the development metabolic comorbidities. Weight loss is the recommended treatment, but success is difficult due to the poor satiety control. Yeast beta-glucans are known as biological modifiers because of their innumerable functions reported in studies with mice and humans, but only one study with dogs was found. This study aimed to evaluate the effects of a diet supplemented with 0.1% beta-glucan on glucose, lipid homeostasis, inflammatory cytokines and satiety parameters in obese dogs. Fourteen dogs composed three experimental groups: Obese group (OG) with seven dogs with body condition score (BCS) 8 or 9; Lean group (LG) included seven non-obese dogs with a BCS of 5; and Supplemented Obese group (SOG) was the OG dogs after 90 days of consumption of the experimental diet. Results Compared to OG, SOG had lower plasma basal glycemic values (p = 0.05) and reduced serum cholesterol and triglyceride levels. TNF-α was lower in SOG than in OG (p = 0.05), and GLP-1 was increased in SOG compared to OG and LG (p = 0.02). Conclusion These results are novel and important for recognizing the possibility of using beta-glucan in obesity prevention and treatment.

Metabolic and immunological phenotype of rare lipomatoses: Dercum’s disease and Roch-Leri mesosomatic lipomatosis

Context Dercum’s disease (DD) and Roch-Leri mesosomatic lipomatosis (LMS) are rare and poorly characterized diseases. The clinical presentation combines multiple lipomas, painful in DD in contrast with LMS, without lipoatrophy. Objective To identify any specific metabolic and immune phenotype of DD and LMS. Design and patients This monocentric retrospective study included 46 patients: 9 DD, 11 LMS, 18 lean and 8 obese controls. Metabolic and immunohematological characteristics of each group were compared. Results The median age of the patients was similar in the 3 groups (31 years). The number of women, and of basophils, and CD3+, CD4+ and CD8+ T lymphocytes was significantly higher in the DD versus the LMS group, without any difference of the metabolic parameters. Weight, BMI, blood pressure, gamma-GT, leptin, fasting insulin and C-peptide levels, fat mass percentage, and intra/total abdominal fat ratio were significantly higher in each lipomatosis group compared with the lean group. Compared with the lean group, the DD group had significantly higher fasting blood glucose, LDL-cholesterol, platelets, leukocytes, basophils, and a lower NK cell count, whereas the LMS group had a significantly lower rate of CD3, CD4, and CD8 lymphocytes. Compared with the obese controls, basophils remained higher in DD and T lymphocytes subpopulations lower in LMS groups. Conclusion DD and LMS show a common background of obesity and metabolic phenotype, but a distinct immunohematological profile characterized by a higher number of basophils in DD patients, an inflammatory profile that could contribute to pain. T lymphocyte depletion was present in LMS. These findings could offer specific therapeutic opportunities, especially for painful DD.

A potential role for insulin treatment during pregnancy in reducing postpartum psychological distress in maternal obesity: an administrative population health study

Background Studies have found an association between obesity and an increased risk for peripartum depression, which has also been linked to decreased placental lactogen levels. In addition, women with obesity treated for gestational diabetes with insulin were found to have increased levels of placental lactogen. Treatment options exist for perinatal and postpartum depression however they pose a risk to the developing offspring. Thus, prevention as well as markers for early identification of peripartum depression are needed. Therefore, our study objective is to identify the association between insulin treatment in pregnancy and the risk of postpartum psychological distress (abbreviated here as PPD) among cohorts of women with and without obesity. Methods Administrative health data (2002/03–2018/19) were used to identify a cohort of women (age 15+ years) who gave birth (N = 250,746) and had no pre-existing mood/anxiety disorders or diabetes (N = 222,863 excluded). Women were then divided into two groups: lean (N = 17,975) and with obesity (N = 9908), which was identified by a recorded maternal weight of > 38 to < 65.6 kg and ≥ 85 to < 186 kg (respectively). The risk of PPD within one year after delivery with and without insulin treatment was assessed by Poisson regression analysis. Models were adjusted for maternal age group (at pregnancy start date) and area-level income (at delivery). Results The unadjusted risk of PPD was higher in the obesity group (8.56%; 95% CI 8.00–9.15) than in the lean group (6.93%; 95% CI 6.56–7.33). When no insulin treatment was given during pregnancy, mothers with obesity had a significantly higher risk of PPD than the lean group (aRR 1.27; 95% CI 1.17–1.39; p < 0.0001). However, when women with obesity and insulin treatment were compared to the lean group with no insulin treatment, no significant difference in the risk of PPD was observed between the groups (aRR 1.30; 95% CI 0.83–2.02; p = 0.248). Conclusion This is the first study to demonstrate a positive association between insulin treatment in pregnancy among women with obesity and reduced PPD rates, suggesting insulin as a possible preventative measure. However, the biological mechanism behind the observed positive effect of insulin on PPD rates remains to be investigated.

The Association of obesity with postoperative hypoxia: A meta-analysis

Post-operative hypoxia is a fairly common clinical complication with severe consequences that can result in permanent organ damage, increased morbidity, increased cost, poor prognosis, and increased fatality. To effectively understand the factors that contribute to such a disease, we conducted a study to determine if obesity is a risk factor of post-operative hypoxia. A thorough search for articles was conducted on various databases. A total of 15658 potential studies were identified out of which 8 were included in this meta-analysis. Data was extracted and analyzed which included 2500 subjects; 1265 subjects in the obese group, and 1235 subjects in the lean group. The combined effect size was 0.19. The results showed that the incidence of post-operative hypoxia in obese was not significantly higher than the lean patients. In conclusion, the meta-analysis reveals that there is no significant correlation between obesity and postoperative hypoxia. Key words: Meta-analysis; Hypoxia; Obesity; Postoperative; Risk factor Citation: Ting Y, Bin L. Association of obesity with postoperative hypoxia: A meta-analysis. Anaesth. Pain intensive care 2021;25(1):55-62. DOI: 10.35975/apic.v25i1.1335 Received: 18 February 2020, Reviewed: 16 March 2020, Accepted: 30 April 2020

A potential role for insulin treatment during pregnancy in reducing postpartum psychological distress in maternal obesity: An administrative population health study

Background: Studies have found an association between obesity and an increased risk for peripartum depression, which has also been linked to decreased placental lactogen levels. In addition, women with obesity treated for gestational diabetes with insulin were found to have increased levels of placental lactogen. Treatment options exist for perinatal and postpartum depression however, they pose a risk to the developing offspring. Thus, prevention as well as markers for early identification of peripartum depression are needed. Therefore, our study objective is to identify the association between insulin treatment in pregnancy and the risk of postpartum psychological distress (abbreviated here as PPD) among cohorts of women with and without obesity. Methods: Administrative health data (2002/03-2018/19) were used to identify a cohort of women (age 15+ years) who gave birth (N=250,746) and had no pre-existing mood/anxiety disorders or diabetes (N=222,863 excluded). Women were then divided into two groups: lean (N=17,975) and with obesity (N=9,908), which was identified by a recorded maternal weight of >38 - <65.6 kg and ≥85 - <186 kg (respectively). The risk of PPD within one year after delivery with and without insulin treatment was assessed by Poisson regression analysis. Models were adjusted for maternal age group (at pregnancy start date) and area-level income (at delivery). Results: The unadjusted risk of PPD was higher in the obesity group (8.56%; 95% CI 8.00 - 9.15) than in the lean group (6.93%; 95% CI 6.56 - 7.33). When no insulin treatment was given during pregnancy, mothers with obesity had a significantly higher risk of PPD than the lean group (aRR 1.27; 95% CI 1.17-1.39; p<0.0001). However, when women with obesity and insulin treatment were compared to the lean group with no insulin treatment, no significant difference in the risk of PPD was observed between the groups (aRR 1.30; 95% CI 0.83-2.02; p=0.248). Conclusion: This is the first study to demonstrate a positive association between insulin treatment in pregnancy among women with obesity and reduced PPD rates, suggesting insulin as a possible preventative measure. However, the biological mechanism behind the observed positive effect of insulin on PPD rates remains to be investigated.

A potential role for insulin treatment during pregnancy in reducing postpartum psychological distress in maternal obesity: An administrative population health study

Background: Studies have found an association between obesity and an increased risk for peripartum depression, which has also been linked to decreased placental lactogen levels. In addition, women with obesity treated for gestational diabetes with insulin were found to have increased levels of placental lactogen. Treatment options exist for perinatal and postpartum depression however, they pose a risk to the developing offspring. Thus, prevention as well as markers for early identification of peripartum depression are needed. Therefore, our study objective is to identify the association between insulin treatment in pregnancy and the risk of postpartum psychological distress (abbreviated here as PPD) among cohorts of women with and without obesity.Methods: Administrative health data (2002/03-2018/19) were used to identify a cohort of women (age 15+ years) who gave birth (N=250,746) and had no pre-existing mood/anxiety disorders or diabetes (N=222,863 excluded). Women were then divided into two groups: lean (N=17,975) and with obesity (N=9,908), which was identified by a recorded maternal weight of >38 - <65.6 kg and ≥85 - <186 kg (respectively). The risk of PPD within one year after delivery with and without insulin treatment was assessed by Poisson regression analysis. Models were adjusted for maternal age group (at pregnancy start date) and area-level income (at delivery).Results: The unadjusted risk of PPD was higher in the obesity group (8.56%; 95% CI 8.00 - 9.15) than in the lean group (6.93%; 95% CI 6.56 - 7.33). When no insulin treatment was given during pregnancy, mothers with obesity had a significantly higher risk of PPD than the lean group (aRR 1.27; 95% CI 1.17-1.39; p<0.0001). However, when women with obesity and insulin treatment were compared to the lean group with no insulin treatment, no significant difference in the risk of PPD was observed between the groups (aRR 1.30; 95% CI 0.83-2.02; p=0.248).Conclusion: This is the first study to demonstrate a positive association between insulin treatment in pregnancy among women with obesity and reduced PPD rates, suggesting insulin as a preventative measure, and further supporting placental lactogen levels as a potential marker for early identification.

A Potential Role for Insulin Treatment During Pregnancy in Reducing Postpartum Psychological Distress in Maternal Obesity: An Administrative Population Health Study

Background: Obesity in pregnancy carries significant risks on mother and child. Studies have found an association between obesity and increased risk for peripartum depression, which has also been linked to decreased placental lactogen levels. In addition, women with obesity treated for gestational diabetes with insulin were found to have increased levels of placental lactogen. Treatment options exist for perinatal and postpartum depression however, they pose a risk to the developing offspring. Thus, prevention as well as markers for early identification of peripartum depression are needed. Methods: Administrative health data (2002/03-2018/19) housed at the Manitoba Centre for Health Policy were used to identify the association between insulin treatment in pregnancy and the risk of postpartum psychological distress (abbreviated here as PPD). This was effectuated in a cohort of women (age 15+ years) who gave birth (N=250,746) and had no pre-existing mood/anxiety disorders or diabetes (N=222,863 excluded). Women were then divided into two groups: lean (N=17,975) and with obesity (N=9,908), which was identified by a recorded maternal weight of >38 - <65.6 kg and ≥85 - <186 kg (respectively). The risk of PPD within one year after delivery with and without insulin treatment was assessed by Poisson regression analysis. Models were adjusted for maternal age group (at pregnancy start date) and area-level income (at delivery). Results: The unadjusted risk of PPD was higher in the obesity group (8.56%; 95% CI 8.00 - 9.15) than in the lean group (6.93%; 95% CI 6.56 - 7.33). When no insulin treatment was given during pregnancy, mothers with obesity had a significantly higher risk of PPD than the lean group (aRR 1.27; 95% CI 1.17-1.39; p<0.0001). However, when women with obesity and insulin treatment were compared to the lean group with no insulin treatment, no significant difference in the risk of PPD was observed between the groups (aRR 1.30; 95% CI 0.83-2.02; p=0.248). Conclusion: This is the first study to demonstrate a positive association between insulin treatment in pregnancy among women with obesity and reduced PPD rates, suggesting insulin as a preventative measure, and further supporting placental lactogen levels as a potential marker for early identification.

High-fat diet-induced obesity and impairment of brain neurotransmitter pool

Obesity and the brain are linked since the brain can control the weight of the body through its neurotransmitters. The aim of the present study was to investigate the effect of high-fat diet (HFD)-induced obesity on brain functioning through the measurement of brain glutamate, dopamine, and serotonin metabolic pools. In the present study, two groups of rats served as subjects. Group 1 was fed a normal diet and named as the lean group. Group 2 was fed an HFD for 4 weeks and named as the obese group. Markers of oxidative stress (malondialdehyde, glutathione, glutathione-s-transferase, and vitamin C), inflammatory cytokines (interleukin [IL]-6 and IL-12), and leptin along with a lipid profile (cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein levels) were measured in the serum. Neurotransmitters dopamine, serotonin, and glutamate were measured in brain tissue. Fecal samples were collected for observing changes in gut flora. In brain tissue, significantly high levels of dopamine and glutamate as well as significantly low levels of serotonin were found in the obese group compared to those in the lean group (P > 0.001) and were discussed in relation to the biochemical profile in the serum. It was also noted that the HFD affected bacterial gut composition in comparison to the control group with gram-positive cocci dominance in the control group compared to obese. The results of the present study confirm that obesity is linked to inflammation, oxidative stress, dyslipidemic processes, and altered brain neurotransmitter levels that can cause obesity-related neuropsychiatric complications.

P1831ABPM DIFFERENCE BETWEEN OBESE AND NON OVERWEIGHT HYPERTENSIVE CHILDREN

Background and Aims The goal of our study was to analyze the difference in ABPM pattern in overweight and non overweight hypertensive children Method The ABPM were performed using Spacelab 90207 and recorded over 24h.Readings were taken every 15 minutes while awake,and every 20 minutes while asleep. In both groups were evaluated the 24h MAP,daytime MAP,nocturnal MAP, systolic and diastolic load,mean 24h SBP and DBP. A total of 108 pts were enrolled. Pts were divided in two groups.In the first group 54 pts non overweight with primary hypertension:33 male and 21 female with mean age of 10.4 y. In the second group the obese hypertensive children, with mean age of 10.5 y, were divided into two subgroups according to BMI Z-scores:subgroup 1 BMI Z-score &gt;2&lt;3 n 40 pts (17 f;21m); subgroup 2 BMI Z-score &gt;3 n (4f;10m). Results Systolic load was significantly higher in obese group (p 0,0409).In obese group n.12 were dipper (22,2%).Obese with BMI zscore &gt;3 was all non dipper (n14 ;100%). In the lean group n 26 was dipper (48.1%),and 28 (51.8%) non dipper. 24 h MAP, Systolic and Diastolic load were significantly higher (p 0,0001) in the obese with BMI z score &gt;3 compared to the lean group. Conclusion The statistically significant pathological pattern among obese is the increase inmean PAS and systolic load, as well as the absence of night dipping in severe obese. The increase in systolic load is already evident in obese mild.This gives a significant predictive value of cardiovascular damage to ABPM which increases with the severity of obesity worse.

0035 Resting Metabolism and the Metabolic Response to Exercise Follow Circadian Patterns with Day/Night Differences in Substrate Utilization Between Lean and Obese Adults

Introduction Resting energy expenditure (EE) follows a circadian rhythm in healthy lean participants, with a nadir in the early morning hours. We determined: (1) whether this pattern persists (or how substrate utilization may change), when challenged with exercise, and; (2) whether obesity affects these responses. Methods Fourteen participants (aged 48.5±12.8y; 6-female; 5-obese, BMI 31.9±1.4kg/m2 [avg±SD]) underwent a 5-day inpatient forced desynchrony protocol, comprised of ten 5h 20min ‘days’ in dim-lighting and free of time cues. Resting EE was measured immediately prior to a 15-minute cycle ergometer exercise bout at 50% of estimated heart rate maximum. Substrate utilization was determined from the respiratory quotient (RQ). Circadian phase was calculated using the salivary dim-light melatonin onset (&gt;3pg/mL threshold). EE data were analyzed using a mixed-effect model with group (lean vs. obese) and circadian phase as fixed factors; subject was a random factor. RQ was analyzed using t-tests to determine day/night differences in groups at rest and in response to exercise. Results Resting and exercising EE both displayed endogenous circadian rhythms (p&lt;0.05) with nadirs in the early morning (~5:30am), without any differences between groups (p&gt;0.22). Resting RQ was similar between the day and night in the lean group (p=0.66), but decreased (suggesting lower carbohydrate utilization) at night within the obese group (-2.5±1.6%, p=0.02). The lean group increased RQ in response to exercise both during the day (+8.9±2.8%) and night (+8.0±2.8%) (both p&lt;0.001), but there was no increase in RQ in the obese group during either day or night exercise (p&gt;0.16). Conclusion These data demonstrate that EE during rest and exercise follows a circadian pattern, with limited influence of obesity. Circadian differences in substrate utilization between lean and obese in the resting state and in response to exercise may play a role in expression and maintenance of unwanted weight gain and impaired metabolic health. Support R01HL125893, R01HL140577, KL2TR002370, K01HL146992, F32HL131308, Medical Research Foundation of Oregon, Ford Foundation, and CTSA grant (UL1TR000128)